Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata J M, Wang H G, Shabaik A, Tudor G, Krajewski S, Myers T G, Johnson G S, Sausville E A, Reed J C
Burnham Institute, Cancer Research Center, La Jolla, California 92037, USA.
Am J Pathol. 1998 Jan;152(1):51-61.
The BAD protein is a pro-apoptotic member of the Bcl-2 family whose ability to heterodimerize with survival proteins such as Bcl-X(L) and to promote cell death is inhibited by phosphorylation. Monoclonal antibodies were generated against the human BAD protein and used to evaluate its expression by immunoblotting and immunohistochemistry in normal human tissues and by immunoblot analysis of the National Cancer Institute anti-cancer drug screening panel of 60 human tumor cell lines. BAD protein was detectable by immunoblotting in many normal tissues, with testis, breast, colon, and spleen being among those with the highest steady-state levels. Immunostaining of tissues revealed many examples of cell-type-specific expression of BAD, suggesting dynamic regulation of BAD protein levels in vivo. In many types of normal cells, BAD immunoreactivity was associated with cytosolic organelles resembling mitochondria, suggesting that BAD is often heterodimerized with other Bcl-2 family proteins in vivo. The relative levels of BAD protein varied widely among established human tumor cell lines, with colon, lung, and melanomas generally having the highest expression. As a group, hematopoietic and lymphoid lines contained the least BAD protein. The BAD protein derived from 11 of 41 tumor lines that expressed this pro-apoptotic protein migrated in gels as a clear doublet, consistent with the presence of hyperphosphorylated BAD protein. Taken together, these findings define for the first time the normal cell-type-specific patterns of expression and intracellular locations of the BAD protein in vivo and provide insights into the regulation of this pro-apoptotic Bcl-2 family protein in human tumors.
BAD蛋白是Bcl-2家族中一种促凋亡成员,其与诸如Bcl-X(L)等存活蛋白形成异二聚体以及促进细胞死亡的能力会受到磷酸化的抑制。针对人BAD蛋白制备了单克隆抗体,并用于通过免疫印迹和免疫组化评估其在正常人体组织中的表达,以及通过对美国国立癌症研究所60种人类肿瘤细胞系的抗癌药物筛选面板进行免疫印迹分析。通过免疫印迹在许多正常组织中可检测到BAD蛋白,睾丸、乳腺、结肠和脾脏是稳态水平最高的组织之一。组织的免疫染色揭示了BAD细胞类型特异性表达的许多实例,表明体内BAD蛋白水平受到动态调节。在许多类型的正常细胞中,BAD免疫反应性与类似线粒体的胞质细胞器相关,这表明BAD在体内常与其他Bcl-2家族蛋白形成异二聚体。BAD蛋白的相对水平在已建立的人类肿瘤细胞系中差异很大,结肠、肺和黑色素瘤通常表达最高。作为一个群体,造血和淋巴系所含的BAD蛋白最少。在表达这种促凋亡蛋白的41种肿瘤细胞系中的11种中,所产生的BAD蛋白在凝胶中迁移为清晰的双峰,这与存在过度磷酸化的BAD蛋白一致。综上所述,这些发现首次确定了体内BAD蛋白正常的细胞类型特异性表达模式和细胞内定位,并为这种促凋亡Bcl-2家族蛋白在人类肿瘤中的调节提供了见解。